TRK 380

Drug Profile

TRK 380

Alternative Names: Beta-3 adrenoceptor agonist - Toray/Taiho; TAC-301; TRK-380

Latest Information Update: 06 Apr 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toray
  • Class
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Overactive bladder

Most Recent Events

  • 06 Apr 2016 No recent reports on development identified - Phase-I for Overactive bladder in Japan (Unspecified)
  • 30 Mar 2012 Taiho Pharmaceuticals and Toray terminate their agreement to co-develop and commercialise TRK 380 for Overactive bladder in Japan
  • 01 Jan 2011 Phase-I clinical trials in Overactive bladder in Japan (Unspecified)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top